Daix (France), Long Island City (New York, USA)
September 7, 2022
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with a need Unsatisfied Medical, today announces that its management team will present the Company’s financial results for the first half of 2022 on Thursday, September 22, 2022, during a webcast presentation.
Inventiva’s first-half 2022 financial results will be released on Wednesday September 21, 2022 at 4:00 p.m. (New York), 10:00 p.m. (Paris).
A conference call
followed by a question and answer session, moderated by Frédéric Cren, Chairman and CEO and co-founder of Inventiva, Pierre Broqua, Scientific Director and co-founder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman , Medical Director of Inventiva, will be held in English
the
Thursday, September 22, 2022
at 8 a.m. (New York), 2 p.m. (Paris).
The conference call and the presentation slides can be followed simultaneously at
next :
https://edge.media-server.com/mmc/p/v5uzhkr8
and will also be available on Inventiva’s website in the “Investors” – “Financial results” section.
In order to receive the access information necessary to participate in the conference call, it is required to register in advance.
through the following link:
https://register.vevent.com/register/BI3a0c8ee6960a4b7a9db4026550ff3f51
.
Within 10 minutes prior to the start time of the conference, participants must use the conference access information provided in the e-mail received at the time of registration (dial-in number and access code ).
The conference call and presentation will be available online
replay
after the event at the following address:
http://inventivapharma.com/en/investors/financial-results-presentations/
.
About Inventiva
Inventiva is a biopharmaceutical company specializing in the research and development of orally administered small molecules for the treatment of patients with NASH and other diseases with significant unmet medical needs. The Company has significant experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Lanifibranor, Inventiva’s most advanced drug candidate, is currently being evaluated in the pivotal Phase III NATiV3 clinical study for the treatment of adult patients with NASH, a common and progressive chronic liver disease, for which it is there is currently no approved treatment.
The Company has entered into a strategic partnership with AbbVie in the field of autoimmune diseases which led to the discovery of the drug candidate cedirogant (ABBV-157), an orally administered RORγ inverse agonist whose efficacy in adult patients with moderate to severe plaque psoriasis is being evaluated in a Phase IIb clinical study conducted by AbbVie. Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended its clinical efforts with odiparcil and is reviewing all available options to optimize its development. Inventiva is in the process of selecting a drug candidate in oncology as part of its program dedicated to the Hippo signaling pathway.
The Company has a scientific team of approximately 80 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. Inventiva has a chemical library of around 240,000 molecules, of which around 60% are exclusive to the Company, as well as its own laboratories and equipment.
Inventiva is listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
www.inventivapharma.com
.
contacts
Attachment
Inventiva – PR – Webcast invitation H1 2022 – 07 09 2022 – FR